96 related articles for article (PubMed ID: 25425971)
1. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
Wiegering A; Korb D; Thalheimer A; Kämmerer U; Allmanritter J; Matthes N; Linnebacher M; Schlegel N; Klein I; Ergün S; Germer CT; Otto C
Neoplasia; 2014 Nov; 16(11):972-81. PubMed ID: 25425971
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.
Bhattacharya A; Tóth K; Sen A; Seshadri M; Cao S; Durrani FA; Faber E; Repasky EA; Rustum YM
Clin Colorectal Cancer; 2009 Jul; 8(3):155-62. PubMed ID: 19632930
[TBL] [Abstract][Full Text] [Related]
4. DNMT1-mediated NR3C1 DNA methylation enables transcription activation of connexin40 and augments angiogenesis during colorectal cancer progression.
Zhai P; Zhang H; Li Q; Yang M; Guo Y; Xing C
Gene; 2024 Jan; 892():147887. PubMed ID: 37813207
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis.
Egidi MJ; Krug S; Haybaeck J; Michl P; Griesmann H
Br J Cancer; 2023 Oct; 129(8):1225-1237. PubMed ID: 37620408
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.
Donnard E; Asprino PF; Correa BR; Bettoni F; Koyama FC; Navarro FC; Perez RO; Mariadason J; Sieber OM; Strausberg RL; Simpson AJ; Jardim DL; Reis LF; Parmigiani RB; Galante PA; Camargo AA
Oncotarget; 2014 Oct; 5(19):9199-213. PubMed ID: 25193853
[TBL] [Abstract][Full Text] [Related]
7. Anticancer and anti-angiogenic activities of mannooligosaccharides extracted from coconut meal on colorectal carcinoma cells
Pason P; Tachaapaikoon C; Suyama W; Waeonukul R; Shao R; Wongwattanakul M; Limpaiboon T; Chonanant C; Ngernyuang N
Toxicol Rep; 2024 Jun; 12():82-90. PubMed ID: 38259721
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
[TBL] [Abstract][Full Text] [Related]
9. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
10. JAK/STAT pathway regulation of GABAA receptor expression after differing severities of experimental TBI.
Raible DJ; Frey LC; Del Angel YC; Carlsen J; Hund D; Russek SJ; Smith B; Brooks-Kayal AR
Exp Neurol; 2015 Sep; 271():445-56. PubMed ID: 26172316
[TBL] [Abstract][Full Text] [Related]
11. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
[TBL] [Abstract][Full Text] [Related]
12. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib in radioiodine-refractory thyroid cancer.
Lee HJ; Yun HJ; Kim S
N Engl J Med; 2015 May; 372(19):1868. PubMed ID: 25946296
[No Abstract] [Full Text] [Related]
14. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling.
Dong Y; Zhang T; Li J; Deng H; Song Y; Zhai D; Peng Y; Lu X; Liu M; Zhao Y; Yi Z
PLoS One; 2014; 9(12):e113830. PubMed ID: 25485753
[TBL] [Abstract][Full Text] [Related]
15. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
Gill S; Dowden S; Colwell B; Collins LL; Berry S
Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503).
Iwasa S; Okita N; Kuchiba A; Ogawa G; Kawasaki M; Nakamura K; Shoji H; Honma Y; Takashima A; Kato K; Hamaguchi T; Boku N; Yamada Y
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817132
[TBL] [Abstract][Full Text] [Related]
17. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
18. Resistance of Lenvatinib in Hepatocellular Carcinoma.
Guo J; Zhao J; Xu Q; Huang D
Curr Cancer Drug Targets; 2022; 22(11):865-878. PubMed ID: 36267045
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
